Finance

Beta
Lists
TRVI:NASDAQ
Trevi Therapeutics Inc
$17.38
-1.86%
(-0.33) 1D
$17.40
+0.12% (+0.020)
After hours
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVI...
Open
$17.49
High
$18.16
Low
$17.34
Mkt. cap
2.47B
Avg. vol.
1.36M
Volume
0.00
52-wk high
$18.16
52-wk low
$5.41
EPS
-$0.32
Beta
1.04
Shares outstanding
141.98M
No. of employees
34
Open
$17.49
High
$18.16
Low
$17.34
Mkt. cap
2.47B
Avg. vol.
1.36M
Volume
0.00
52-wk high
$18.16
52-wk low
$5.41
EPS
-$0.32
Beta
1.04
Shares outstanding
141.98M
No. of employees
34
News stories
From sources across the web
About Trevi Therapeutics Inc
CEO-
Employees34
Founded2011
HeadquartersNew Haven, Connecticut, United States
SectorPharmaceutical industry
Websitetrevitherapeutics.com
Analyst Ratings
Based on 7 analysts giving stock ratings to TRVI in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TRVI in the last 3 months.
Highest
Current $17.38
$30.00 (+72.61%)
Average
$24.43 (+40.56%)
Lowest
$20.00 (+15.07%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Serge Belanger
Needham
Buy
Maintained
$23.00
+32.3%
05/20/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$24.00
+38.1%
05/08/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$29.00
+66.9%
05/07/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$24.00
+38.1%
05/06/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$30.00
+72.6%
05/08/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$21.00
+20.8%
05/08/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$20.00
+15.1%
05/05/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$25.00
+43.8%
03/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.39M
10.08M
6.19M
9.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.33M
3.83M
4.03M
4.97M
Operating expense
13.72M
13.92M
10.22M
14.91M
Total operating expenses
13.72M
13.92M
10.22M
14.91M
Operating income
-13.72M
-13.92M
-10.22M
-14.91M
Other non operating income
-7.00K
-2.00K
-15.00K
-
EBT including unusual items
-12.32M
-11.82M
-8.33M
-13.21M
EBT excluding unusual items
-12.32M
-11.82M
-8.33M
-13.21M
Income tax expense
-21.00K
-15.00K
-16.00K
-20.00K
Effective tax rate
0.17%
0.13%
0.19%
0.15%
Other operating expenses
-
-
-
-
Net income
-12.30M
-11.80M
-8.32M
-13.19M
Net profit margin
-
-
-
-
Earnings per share
-0.09
-0.08
-0.06
-0.09
Interest and investment income
1.41M
2.10M
1.90M
1.70M
Interest expense
-
-
-
-
Net interest expenses
1.41M
2.10M
1.90M
1.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.68M
-13.88M
-10.19M
-14.88M
Gain or loss from assets sale
-
-
7.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer